Moricizine

Summary

Moricizine (CHEMBL1075) is an approved small-molecule anti-arrhythmia drug (ATC C01BG01); indicated across 2 conditions including atrial fibrillation.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01BG01
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 427.5 Da · C22H25N3O4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1075
Name	Moricizine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	34633
ChEBI	CHEBI:6997
ATC	C01BG01
Molecular formula	C22H25N3O4S
Molecular weight	427.5
InChIKey	FUBVWMNBEHXPSU-UHFFFAOYSA-N

SMILES: CCOC(=O)NC1=CC2=C(C=C1)SC3=CC=CC=C3N2C(=O)CCN4CCOCC4

IUPAC name: ethyl N-[10-(3-morpholin-4-ylpropanoyl)phenothiazin-2-yl]carbamate

ChEBI definition: A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.

Pharmacological roles (ChEBI): anti-arrhythmia drug.

Also known as: EN-313, EN-313 FREE BASE, Moracizina, Moracizine, Moricizine, SID11112721, SID50086819, moricizine, MORICIZINE, MORACIZINE, SID174006664, moracizine

Parent form; salt/anhydrous children: CHEMBL1200334

Patent coverage: 1,128 distinct patent families (3,860 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,841 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Voltage-gated inwardly rectifying potassium channel KCNH2, 3’,5’-cyclic-AMP phosphodiesterase 4D, Cytochrome P450 3A4, Nuclear receptor subfamily 1 group I member 2, Hypoxia-inducible factor 1-alpha.

Bioactivity

ChEMBL activities: 6 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDE4D	6.11	AC50	770	nM	CHEMBL_ACT_25185771
HIF1A	5.8	Potency	1585	nM	CHEMBL_ACT_4125717
HIF1A	5.8	Potency	1585	nM	CHEMBL_ACT_4519926
CYP3A4	5.3	Potency	5012	nM	CHEMBL_ACT_4973702
CYP3A4	5.3	Potency	5012	nM	CHEMBL_ACT_5042728
CYP3A4	5.3	AC50	5012	nM	CHEMBL_ACT_6053592

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
atrial fibrillation	3	MONDO:0004981	EFO:0000275

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000526	PHASE3	COMPLETED	Cardiac Arrhythmia Suppression Trial (CAST)
NCT00000556	PHASE3	COMPLETED	Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
NCT00000504	PHASE2	COMPLETED	Cardiac Arrhythmia Pilot Study (CAPS)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).